Hanmi Financial Corp. 8-K Summary
Business Context and Reporting Period
This Form 8-K Current Report was filed by Hanmi Financial Corporation on November 9, 2004, regarding events occurring on November 4, 2004. The filing discloses a significant change in executive leadership and the terms of a new employment agreement.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation and appointment details.
Material Changes
- Executive Appointment: Dr. Sung Won Sohn (59) was appointed as President and Chief Executive Officer, effective January 3, 2005.
- Executive Departure: Mr. Jae Whan Yoo will step down as President, CEO, and Director on December 31, 2004.
- Board Membership: Dr. Sohn will join the Board of Directors upon commencing employment.
Guidance, Outlook, and Compensation Terms
The filing details the material terms of Dr. Sohn's employment contract, which expires on January 3, 2011, unless terminated earlier:
- Base Salary: $550,000 annually, adjusted for inflation.
- Cash Bonus: Up to 125% of base salary based on performance; guaranteed minimum of 50% in the first year.
- Equity Grants:
- Stock options for 175,000 shares (vesting 16.66% annually).
- Restricted stock grant of 50,000 shares (vesting 20% annually).
- Performance-based options for an additional 200,000 shares if stock price or EPS doubles and then quadruples.
- Severance: Includes base salary for the remainder of the contract term, continued vesting of awards, and health benefits if terminated without cause or constructively terminated.
- Change in Control: Triggers lump-sum severance, immediate vesting of all unvested awards, and a cash bonus equal to the average of the preceding three years' bonuses.
Investor Verification Checklist
- Verify the exact start date of Dr. Sohn's tenure (January 3, 2005) and the transition period with Mr. Yoo.
- Review the specific performance objectives established by the Compensation Committee for the cash incentive bonus.
- Confirm the total potential equity exposure, including the conditional grants tied to stock price and EPS growth.
- Assess the impact of the severance package on future cash flow obligations in the event of termination.